From a procedural standpoint, although no data for only FNA-PTH is available, FNAC is contraindicated in suspected PC for two key reasons: first, cytology cannot reliably differentiate benign from malignant parathyroid lesions due to overlapping cellular morphology; and second, there is a risk of tumor seeding along the needle tract, potentially leading to local recurrence or dissemination of malignant cells [22,23,24]. Here, PTH is linked to neoplasm.